12 Yue 3 mazuva, chidzidzo "The Lancet" chakaburitswa pamhepo, che CD30 -positive yekunze peripheral T -cell lymphoma varwere, rituximab iyi, cyclophosphamide, doxorubicin uye prednisone ( A + CHP Zvirinani kupfuura cyclophosphamide, doxorubicin, vincristine uye prednisone ( CHOP ).
Steven Horwitz , MD, kubva kuChirangaridzo Sloan Kettering Cancer Center muNew York City uye vaaishanda navo vakaita kaviri-mapofu, placebo-inodzorwa, inoshingaira-kutonga chikamu 3 chidzidzo chinosanganisira varwere ve452 kubva kunzvimbo dze132 munyika dze17. Varwere ava CD30-positive peripheral T-cell lymphoma vasina kurapwa kare. Varwere vane 1: 1 random allocation ratio, inogamuchira A + CHP kana yeCHOP, inotsigirwa 6, kana . 8th 21 inguva yezuva.
Vatsvagiri vakawana kuti yepakati-yekuenderera-isina kupona (PFS) yeboka reA + CHP neboka reCHOP yaive 48.2 uye 20.8 mwedzi, zvichiteerana. Kuitika kwemhedzisiro kwanga kwakafanana pakati pemapoka maviri, kusanganisira febrile neutropenia (18% uye 15%, zvichiteerana) uye peripheral neuropathy (52% uye 55%, zvichiteerana). Zviitiko zvakaipa zvinouraya zvakaitika mu3% uye 4% yevarwere, zvichiteerana.
In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for lymphoma varwere.
